Standard Treatments and Emergency Care for ITP
At a Glance
The goal of ITP treatment is to maintain a safe platelet count to prevent severe bleeding, rather than achieving a completely normal count. Approaches range from observation in children to first-line steroids, second-line platelet-boosting medications, and emergency therapy for acute bleeds.
Managing ITP is a journey that often evolves over time. The goal of treatment is not necessarily to achieve a “normal” platelet count (150,000+), but rather to maintain a safe platelet count—usually above 20,000 to 30,000—that prevents serious bleeding and allows for a high quality of life [1][2].
Pediatric vs. Adult Approaches
The first decision in treatment depends heavily on the patient’s age:
- For Children: Because pediatric ITP often resolves on its own, doctors frequently recommend a “watch and wait” strategy [3]. If the child has only bruising or petechiae (skin signs) and no active bleeding, doctors may simply observe them closely rather than using drugs that might have side effects [4].
- For Adults: Adults are less likely to have a spontaneous recovery. Therefore, treatment is more common, especially if the count is very low or there are signs of bleeding [1].
First-Line Treatments (The First Step)
These are the standard treatments used when ITP is newly diagnosed:
- Corticosteroids: These oral drugs (like prednisone or dexamethasone pills) dampen the immune system’s attack on platelets [1]. They are effective but can cause mood changes, weight gain, and high blood sugar. Crucially, corticosteroids cannot be stopped abruptly. They must be slowly “tapered” down under a doctor’s supervision to prevent severe withdrawals.
- IVIG (Intravenous Immunoglobulin): This is an IV infusion of concentrated antibodies that “distracts” the immune system, providing a rapid but temporary boost in platelets [5][6].
- Anti-D (WinRho): Another IV infusion option for certain patients (those who are Rh-positive and still have their spleen). Like IVIG, it provides a temporary increase in platelets [1].
Second-Line Treatments (Long-Term Management)
If first-line treatments don’t work, or if steroids need to be stopped due to side effects, doctors move to second-line options. Modern guidelines recommend exhausting these medications before considering irreversible surgery [1][7].
- TPO-RAs (Thrombopoietin Receptor Agonists): These drugs stimulate the bone marrow to produce more platelets [8]. They are taken either as a daily oral pill (like eltrombopag or avatrombopag) or a weekly subcutaneous injection (like romiplostim).
- Rituximab: This is a targeted therapy given as a series of IV infusions over a few weeks. It removes the B-cells responsible for making the autoantibodies that attack platelets [9].
- Fostamatinib: A newer, daily oral pill that blocks the specific signaling pathway used by the body to destroy platelets [10][11].
- Splenectomy (Surgery): Surgery to remove the spleen. Because the spleen is the main site of platelet destruction, removing it can lead to long-term remission [12]. However, this is usually considered a “last resort” further down the line, as it carries a lifelong risk of infection and blood clots [13][14].
Emergency Management
In rare cases of life-threatening bleeding (like a brain or severe stomach bleed), doctors use a combination therapy approach. This involves giving high-dose IV steroids, IVIG, and often platelet transfusions all at once in the hospital to raise the count as fast as possible [6][1].
Always discuss the benefits, risks, and administration methods of each tier with your hematologist to find the path that best fits your life [9].
Return to the Home Page.
Common questions in this guide
Is treatment always necessary for children with ITP?
What is considered a safe platelet count for someone with ITP?
What are the first-line treatments for newly diagnosed ITP?
Why do I need to slowly taper off my corticosteroids?
What happens if first-line ITP treatments do not work?
Is removing the spleen a recommended treatment for ITP?
Related questions
Get notified when new evidence is published on Immune thrombocytopenia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives.
Zitek T, Weber L, Pinzon D, Warren N
Open access emergency medicine : OAEM 2022; (14()):25-34 doi:10.2147/OAEM.S331675.
PMID: 35125895 - 2
Proposal of treatment algorithm for immune thromocytopenia in adult patients of a hematology service at a referral center in Northeastern Brazil.
Ribeiro RA, Galiza Neto GC, Furtado ADS, et al.
Hematology, transfusion and cell therapy 2019; (41(3)):253-261 doi:10.1016/j.htct.2018.10.005.
PMID: 31085155 - 3
Multicenter Cohort Study Comparing U.S. Management of Inpatient Pediatric Immune Thrombocytopenia to Current Treatment Guidelines.
Witmer CM, Lambert MP, O'Brien SH, Neunert C
Pediatric blood & cancer 2016; (63(7)):1227-31 doi:10.1002/pbc.25961.
PMID: 26929009 - 4
Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions.
Bergmann S
Clinical case reports 2017; (5(10)):1660-1663 doi:10.1002/ccr3.1086.
PMID: 29026567 - 5
Outcome and response to different management regimens in pediatric patients with immune thrombocytopenia (ITP).
AbdelAziz RA, El-Sayed D, Ahmed FEZ, Komy MA
Annals of hematology 2025; (104(10)):5003-5010 doi:10.1007/s00277-025-06626-1.
PMID: 41003735 - 6
Bleeding complications in immune thrombocytopenia.
Arnold DM
Hematology. American Society of Hematology. Education Program 2015; (2015()):237-42 doi:10.1182/asheducation-2015.1.237.
PMID: 26637728 - 7
Updated guidelines for immune thrombocytopenic purpura: Expanded management options.
DeSouza S, Angelini D
Cleveland Clinic journal of medicine 2021; (88(12)):664-668 doi:10.3949/ccjm.88a.20201.
PMID: 34857604 - 8
Treatment of primary and secondary immune thrombocytopenia.
Kado R, McCune WJ
Current opinion in rheumatology 2019; (31(3)):213-222 doi:10.1097/BOR.0000000000000599.
PMID: 30920453 - 9
Management of immune thrombocytopenia: 2022 update of Korean experts recommendations.
Park YH, Kim DY, Kim S, et al.
Blood research 2022; (57(1)):20-28 doi:10.5045/br.2022.2022043.
PMID: 35342042 - 10
Fostamatinib for the treatment of chronic immune thrombocytopenia.
Connell NT, Berliner N
Blood 2019; (133(19)):2027-2030 doi:10.1182/blood-2018-11-852491.
PMID: 30803989 - 11
Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC, Gebru T, Muslimani A
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2019; (76(11)):789-794 doi:10.1093/ajhp/zxz052.
PMID: 30951590 - 12
Sequence of Splenectomy and Rituximab for the Treatment of Steroid-Refractory Immune Thrombocytopenia: Does It Matter?
Hammond WA, Vishnu P, Rodriguez EM, et al.
Mayo Clinic proceedings 2019; (94(11)):2199-2208 doi:10.1016/j.mayocp.2019.05.024.
PMID: 31685150 - 13
Medical complications following splenectomy.
Buzelé R, Barbier L, Sauvanet A, Fantin B
Journal of visceral surgery 2016; (153(4)):277-86.
PMID: 27289254 - 14
Splenectomy is associated with a higher risk for venous thromboembolism: A prospective cohort study.
Lee DH, Barmparas G, Fierro N, et al.
International journal of surgery (London, England) 2015; (24(Pt A)):27-32.
PMID: 26493210
This page provides educational information about ITP treatment options and is not a substitute for professional medical advice. Always consult your hematologist to determine the safest and most effective treatment plan for your specific platelet count and symptoms.